$18.28
1.16% today
Nasdaq, Apr 02, 09:17 pm CET
ISIN
KYG011251066
Symbol
AFYA

Afya Target price 2025 - Analyst rating & recommendation

Afya Classifications & Recommendation:

Buy
25%
Hold
25%
Sell
50%

Afya Price Target

Target Price $18.53
Price $18.07
Potential
Number of Estimates 8
8 Analysts have issued a price target Afya 2026 . The average Afya target price is $18.53. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 8 analysts: 2 Analysts recommend Afya to buy, 2 to hold and 4 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Afya stock has an average upside potential 2026 of . Most analysts recommend the Afya stock at Sale.

Sales and Margin forecast 2025, 2026 & 2027

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 612.94 655.63
6.46% 6.96%
EBITDA Margin 40.94% 42.73%
13.11% 4.38%
Net Margin 19.15% 20.66%
42.00% 7.91%

8 Analysts have issued a sales forecast Afya 2025 . The average Afya sales estimate is

$656m
Unlock
. This is
6.62% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$670m 8.94%
Unlock
, the lowest is
$646m 5.13%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $613m 6.46%
2025
$656m 6.96%
Unlock
2026
$697m 6.37%
Unlock
2027
$757m 8.59%
Unlock

8 Analysts have issued an Afya EBITDA forecast 2025. The average Afya EBITDA estimate is

$280m
Unlock
. This is
10.94% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$287m 13.51%
Unlock
, the lowest is
$262m 3.91%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $251m 20.41%
2025
$280m 11.65%
Unlock
2026
$299m 6.62%
Unlock
2027
$328m 9.64%
Unlock

EBITDA Margin

2024 40.94% 13.11%
2025
42.73% 4.38%
Unlock
2026
42.84% 0.26%
Unlock
2027
43.25% 0.96%
Unlock

3 Afya Analysts have issued a net profit forecast 2025. The average Afya net profit estimate is

$135m
Unlock
. This is
13.67% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$161m 35.08%
Unlock
, the lowest is
$118m 1.03%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $117m 51.16%
2025
$135m 15.42%
Unlock
2026
$168m 23.79%
Unlock
2027
$255m 52.14%
Unlock

Net Margin

2024 19.15% 42.00%
2025
20.66% 7.91%
Unlock
2026
24.05% 16.41%
Unlock
2027
33.69% 40.08%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 & 2027

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ 1.30 1.50
51.16% 15.38%
P/E 12.04
EV/Sales 3.05

3 Analysts have issued a Afya forecast for earnings per share. The average Afya EPS is

$1.50
Unlock
. This is
13.64% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$1.78 34.85%
Unlock
, the lowest is
$1.31 0.76%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $1.30 51.16%
2025
$1.50 15.38%
Unlock
2026
$1.86 24.00%
Unlock
2027
$2.83 52.15%
Unlock

P/E ratio

Current 13.71 36.59%
2025
12.04 12.18%
Unlock
2026
9.73 19.19%
Unlock
2027
6.39 34.33%
Unlock

Based on analysts' sales estimates for 2025, the Afya stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 3.26 11.17%
2025
3.05 6.30%
Unlock
2026
2.87 5.99%
Unlock
2027
2.64 7.91%
Unlock

P/S ratio

Current 2.65 8.63%
2025
2.49 6.21%
Unlock
2026
2.34 5.99%
Unlock
2027
2.15 7.91%
Unlock

Current Afya Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Morgan Stanley
Locked
Locked
Locked Mar 11 2025
Citigroup
Locked
Locked
Locked Jan 31 2025
JP Morgan
Locked
Locked
Locked Jan 17 2025
Goldman Sachs
Locked
Locked
Locked Dec 03 2024
UBS
Locked
Locked
Locked Aug 30 2024
Analyst Rating Date
Locked
Morgan Stanley:
Locked
Locked
Mar 11 2025
Locked
Citigroup:
Locked
Locked
Jan 31 2025
Locked
JP Morgan:
Locked
Locked
Jan 17 2025
Locked
Goldman Sachs:
Locked
Locked
Dec 03 2024
Locked
UBS:
Locked
Locked
Aug 30 2024

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today